Top

Current HIV/AIDS Reports

Published in:

01-06-2020 | Human Immunodeficiency Virus | HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

Frailty in People Living with HIV

Author: Julian Falutz

Published in: Current HIV/AIDS Reports | Issue 3/2020

Abstract

Purpose of Review

Different factors contribute to the decreased overall long-term survival in treated people living with HIV (PLWH). This paper will review the state of physical frailty which limits successful aging in PLWH.

Recent Findings

Identifiable events on the continuum from clinical normality to heightened risk of adverse health outcomes contribute to frailty. These center on chronic inflammation leading to destabilization of autoregulated physiologic systems challenged by environmental and biologic challenges. Frailty assessment can inform the profile of aging PLWH at increased risk of common age-related disorders and geriatric syndromes. Biologic and psychosocial risk factors promoting progression to and reversion from a dynamic state of frailty are being investigated, allowing for preventative interventions to be considered.

Summary

Insights gained from studying frail PLWH will help adapt an interdisciplinary geriatric model of health care for selected PLWH. This will improve the health and well-being of aging PLWH.

Wallace LM, Theou O, Pena F, Rockwood K, Andrew MK. Social vulnerability as a predictor of mortality and disability: cross-country differences in the survey of health, aging, and retirement in Europe (SHARE). Aging Clin Exp Res. 2015;27(3):365–72. https://doi.org/10.1007/s40520-014-0271-6.CrossRefPubMed

Ruan Q, D'Onofrio G, Sancarlo D, Greco A, Lozupone M, Seripa D, et al. Emerging biomarkers and screening for cognitive frailty. Aging Clin Exp Res. 2017;29(6):1075–86. https://doi.org/10.1007/s40520-017-0741-8.CrossRefPubMed

Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–33. https://doi.org/10.1016/S0140-6736(13)61809-7.CrossRefPubMedPubMedCentral

Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV AIDS. 2016;11(5):492–500. https://doi.org/10.1097/COH.0000000000000298.CrossRefPubMedPubMedCentral

Centers for Disease Control and Prevention. HIV Surveillance Report, 25, . 2013 Published Feb 2015.

Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, Sighem A, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15(7):810–8. https://doi.org/10.1016/S1473-3099(15)00056-0.CrossRefPubMedPubMedCentral

Lerner AM, Eisinger RW, Fauci AS. Comorbidities in persons with HIV: the lingering challenge. JAMA. 2019. https://doi.org/10.1001/jama.2019.19775.CrossRefPubMed

Gross AM, Jaeger PA, Kreisberg JF, Licon K, Jepsen KL, Khosroheidari M, et al. Methylome-wide analysis of chronic HIV infection reveals five-year increase in biological age and epigenetic targeting of HLA. Mol Cell. 2016;62(2):157–68. https://doi.org/10.1016/j.molcel.2016.03.019.CrossRefPubMedPubMedCentral

Leung JM, Fishbane N, Jones M, Morin A, Xu S, Liu JC, et al. Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion. Aging (Albany NY). 2017;9(3):687–705. https://doi.org/10.18632/aging.101184.CrossRef

10.

Cohen J, Torres C. HIV-associated cellular senescence: a contributor to accelerated aging. Ageing Res Rev. 2017;36:117–24. https://doi.org/10.1016/j.arr.2016.12.004.CrossRefPubMed

11.

•• Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci. 2014;69(7):833–42. https://doi.org/10.1093/gerona/glt168. This article introduces the key concepts of accelerated and accentuated aging in regards to the changing clinical profile of PLWH.CrossRefPubMed

12.

Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep. 2012;9(2):139–47. https://doi.org/10.1007/s11904-012-0118-8.CrossRefPubMed

13.

Fulop T, Larbi A, Witkowski JM, McElhaney J, Loeb M, Mitnitski A, et al. Aging, frailty and age-related diseases. Biogerontology. 2010;11(5):547–63. https://doi.org/10.1007/s10522-010-9287-2.CrossRefPubMed

14.

• De Francesco D, Wit FW, Burkle A, Oehlke S, Kootstra NA, Winston A, et al. Do people living with HIV experience greater age advancement than their HIV-negative counterparts? AIDS. 2019;33(2):259–68. https://doi.org/10.1097/QAD.0000000000002063. This paper investigates the important issue of differentiating chronologic and biologic age in PLWH using a multifactorial metric being validated in the general geriatric population.CrossRefPubMed

15.

Rasmussen LD, May MT, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, et al. Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study. Lancet HIV. 2015;2(7):e288–98. https://doi.org/10.1016/S2352-3018(15)00077-6.CrossRefPubMed

16.

• Greene M, Covinsky KE, Valcour V, Miao Y, Madamba J, Lampiris H, et al. Geriatric syndromes in older HIV-infected adults. J Acquir Immune Defic Syndr. 2015;69(2):161–7. https://doi.org/10.1097/QAI.0000000000000556. This important paper broadens the thinking of the emerging clinical profile of aging PLWH to include typical problems normally seen in much older persons.CrossRefPubMedPubMedCentral

17.

• Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007;55(5):780–91. https://doi.org/10.1111/j.1532-5415.2007.01156.x. This is a landmark paper discussing geriatric syndromes.CrossRefPubMedPubMedCentral

18.

•• Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56. https://doi.org/10.1093/gerona/56.3.m146. This is the key paper presenting the concept of frailty as a biologic phenotype.CrossRefPubMed

19.

•• Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. ScientificWorldJournal. 2001;1:323–36. https://doi.org/10.1100/tsw.2001.58. This is the seminal paper discussing frailty as the accumulation of health deficits.CrossRefPubMedPubMedCentral

20.

Buta BJ, Walston JD, Godino JG, Park M, Kalyani RR, Xue QL, et al. Frailty assessment instruments: systematic characterization of the uses and contexts of highly-cited instruments. Ageing Res Rev. 2016;26:53–61. https://doi.org/10.1016/j.arr.2015.12.003.CrossRefPubMed

21.

Rockwood K, Song X, Mitnitski A. Changes in relative fitness and frailty across the adult lifespan: evidence from the Canadian National Population Health Survey. CMAJ. 2011;183(8):E487–94. https://doi.org/10.1503/cmaj.101271.CrossRefPubMedPubMedCentral

22.

Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24. https://doi.org/10.1186/1471-2318-8-24.CrossRefPubMedPubMedCentral

23.

Clegg A, Bates C, Young J, Ryan R, Nichols L, Ann Teale E, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing. 2016;45(3):353–60. https://doi.org/10.1093/ageing/afw039.CrossRefPubMedPubMedCentral

24.

Wong CH, Weiss D, Sourial N, Karunananthan S, Quail JM, Wolfson C, et al. Frailty and its association with disability and comorbidity in a community-dwelling sample of seniors in Montreal: a cross-sectional study. Aging Clin Exp Res. 2010;22(1):54–62. https://doi.org/10.1007/bf03324816.CrossRefPubMed

25.

Theou O, Rockwood MR, Mitnitski A, Rockwood K. Disability and co-morbidity in relation to frailty: how much do they overlap? Arch Gerontol Geriatr. 2012;55(2):e1–8. https://doi.org/10.1016/j.archger.2012.03.001.CrossRefPubMed

26.

Thompson MQ, Theou O, Adams RJ, Tucker GR, Visvanathan R. Frailty state transitions and associated factors in south Australian older adults. Geriatr Gerontol Int. 2018;18(11):1549–55. https://doi.org/10.1111/ggi.13522.CrossRefPubMed

27.

Rockwood K, Andrew M, Mitnitski A. A comparison of two approaches to measuring frailty in elderly people. J Gerontol A Biol Sci Med Sci. 2007;62(7):738–43. https://doi.org/10.1093/gerona/62.7.738.CrossRefPubMed

28.

Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489–95. https://doi.org/10.1503/cmaj.050051.CrossRefPubMedPubMedCentral

29.

Rolfson DB, Majumdar SR, Tsuyuki RT, Tahir A, Rockwood K. Validity and reliability of the Edmonton frail scale. Age Ageing. 2006;35(5):526–9. https://doi.org/10.1093/ageing/afl041.CrossRefPubMedPubMedCentral

30.

Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging. 2012;16(7):601–8. https://doi.org/10.1007/s12603-012-0084-2.CrossRefPubMedPubMedCentral

31.

Vellas B. Implementing frailty screening, assessment, and sustained intervention: the experience of the Gerontopole. J Nutr Health Aging. 2015;19(6):673–80. https://doi.org/10.1007/s12603-015-0505-0.CrossRefPubMed

32.

Bielderman A, van der Schans CP, van Lieshout MR, de Greef MH, Boersma F, Krijnen WP, et al. Multidimensional structure of the Groningen frailty Indicator in community-dwelling older people. BMC Geriatr. 2013;13:86. https://doi.org/10.1186/1471-2318-13-86.CrossRefPubMedPubMedCentral

33.

• Vermeiren S, Vella-Azzopardi R, Beckwee D, Habbig AK, Scafoglieri A, Jansen B, et al. Frailty and the Prediction of Negative Health Outcomes: A Meta-Analysis. J Am Med Dir Assoc. 2016;17(12):1163 e1–e17. https://doi.org/10.1016/j.jamda.2016.09.010. This paper reviews the evidence supporting the clinical consequences of both prefrail and frail states.CrossRef

34.

Fedarko NS. The biology of aging and frailty. Clin Geriatr Med. 2011;27(1):27–37. https://doi.org/10.1016/j.cger.2010.08.006.CrossRefPubMedPubMedCentral

35.

Yao X, Li H, Leng SX. Inflammation and immune system alterations in frailty. Clin Geriatr Med. 2011;27(1):79–87. https://doi.org/10.1016/j.cger.2010.08.002.CrossRefPubMedPubMedCentral

36.

Hubbard RE, Woodhouse KW. Frailty, inflammation and the elderly. Biogerontology. 2010;11(5):635–41. https://doi.org/10.1007/s10522-010-9292-5.CrossRefPubMed

37.

Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A, Pawelec G. Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda). 2008;23:64–74. https://doi.org/10.1152/physiol.00040.2007.CrossRef

38.

Wang GC, Kao WH, Murakami P, Xue QL, Chiou RB, Detrick B, et al. Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am J Epidemiol. 2010;171(10):1144–52. https://doi.org/10.1093/aje/kwq062.CrossRefPubMedPubMedCentral

39.

Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev. 2000;121(1–3):187–201. https://doi.org/10.1016/s0047-6374(00)00210-4.CrossRefPubMed

40.

Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Lofgren S, et al. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci. 2005;60(5):556–65. https://doi.org/10.1093/gerona/60.5.556.CrossRefPubMed

41.

Strindhall J, Nilsson BO, Lofgren S, Ernerudh J, Pawelec G, Johansson B, et al. No immune risk profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study. Exp Gerontol. 2007;42(8):753–61. https://doi.org/10.1016/j.exger.2007.05.001.CrossRefPubMed

42.

Fulop T, Larbi A, Witkowski JM. Human Inflammaging. Gerontology. 2019;65(5):495–504. https://doi.org/10.1159/000497375.CrossRefPubMed

43.

•• Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4–9. https://doi.org/10.1093/gerona/glu057. This paper presents the data supporting the role of chronic inflammation as a driver for age-related conditions.CrossRefPubMed

44.

Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011;10(3):319–29. https://doi.org/10.1016/j.arr.2010.11.002.CrossRefPubMed

45.

Soysal P, Stubbs B, Lucato P, Luchini C, Solmi M, Peluso R, et al. Inflammation and frailty in the elderly: a systematic review and meta-analysis. Ageing Res Rev. 2016;31:1–8. https://doi.org/10.1016/j.arr.2016.08.006.CrossRefPubMed

46.

Clegg A, Hassan-Smith Z. Frailty and the endocrine system. Lancet Diabetes Endocrinol. 2018;6(9):743–52. https://doi.org/10.1016/S2213-8587(18)30110-4.CrossRefPubMed

47.

Landi F, Calvani R, Cesari M, Tosato M, Martone AM, Bernabei R, et al. Sarcopenia as the biological substrate of physical frailty. Clin Geriatr Med. 2015;31(3):367–74. https://doi.org/10.1016/j.cger.2015.04.005.CrossRefPubMed

48.

Jones MJ, Goodman SJ, Kobor MS. DNA methylation and healthy human aging. Aging Cell. 2015;14(6):924–32. https://doi.org/10.1111/acel.12349.CrossRefPubMedPubMedCentral

49.

Haapanen MJ, Perala MM, Salonen MK, Guzzardi MA, Iozzo P, Kajantie E, et al. Telomere length and frailty: the Helsinki birth cohort study. J Am Med Dir Assoc. 2018;19(8):658–62. https://doi.org/10.1016/j.jamda.2018.05.011.CrossRefPubMed

50.

Ho YY, Matteini AM, Beamer B, Fried L, Xue QL, Arking DE, et al. Exploring biologically relevant pathways in frailty. J Gerontol A Biol Sci Med Sci. 2011;66(9):975–9. https://doi.org/10.1093/gerona/glr061.CrossRefPubMed

51.

JafariNasabian P, Inglis JE, Reilly W, Kelly OJ, Ilich JZ. Aging human body: changes in bone, muscle and body fat with consequent changes in nutrient intake. J Endocrinol. 2017;234(1):R37–51. https://doi.org/10.1530/JOE-16-0603.CrossRefPubMed

52.

Hawkins KL, Brown TT, Margolick JB, Erlandson KM. Geriatric syndromes: new frontiers in HIV and sarcopenia. AIDS. 2017;31(Suppl 2):S137–S46. https://doi.org/10.1097/QAD.0000000000001444.CrossRefPubMed

53.

Lake JE, Stanley TL, Apovian CM, Bhasin S, Brown TT, Capeau J, et al. Practical review of recognition and Management of Obesity and Lipohypertrophy in human immunodeficiency virus infection. Clin Infect Dis. 2017;64(10):1422–9. https://doi.org/10.1093/cid/cix178.CrossRefPubMedPubMedCentral

54.

• Bakal DR, Coelho LE, Luz PM, Clark JL, De Boni RB, Cardoso SW, et al. Obesity following ART initiation is common and influenced by both traditional and HIV−/ART-specific risk factors. J Antimicrob Chemother. 2018;73(8):2177–85. https://doi.org/10.1093/jac/dky145. This paper supports the growing concern about the association of currently recommended antiretroviral drugs and increased weight.CrossRefPubMedPubMedCentral

55.

Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Perez-Valero I, Montes ML, et al. Impact of nucleos(t)ide reverse transcriptase inhibitors on blood telomere length changes in a prospective cohort of aviremic HIV-infected adults. J Infect Dis. 2018;218(10):1531–40. https://doi.org/10.1093/infdis/jiy364.CrossRefPubMed

56.

Garrabou G, Lopez S, Moren C, Martinez E, Fontdevila J, Cardellach F, et al. Mitochondrial damage in adipose tissue of untreated HIV-infected patients. AIDS. 2011;25(2):165–70. https://doi.org/10.1097/QAD.0b013e3283423219.CrossRefPubMed

57.

Li M, Foli Y, Liu Z, Wang G, Hu Y, Lu Q, et al. High frequency of mitochondrial DNA mutations in HIV-infected treatment-experienced individuals. HIV Med. 2017;18(1):45–55. https://doi.org/10.1111/hiv.12390.CrossRefPubMed

58.

Ndumbi P, Gilbert L, Tsoukas CM. Comprehensive evaluation of the immune risk phenotype in successfully treated HIV-infected individuals. PLoS One. 2015;10(2):e0117039. https://doi.org/10.1371/journal.pone.0117039.CrossRefPubMedPubMedCentral

59.

• Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078. https://doi.org/10.1371/journal.ppat.1004078. This paper provides evidence that persistent immune dysregulation in PLWH despite effective cART is a risk factor for adverse health events.CrossRefPubMedPubMedCentral

60.

Guaraldi G, Zona S, Silva AR, Menozzi M, Dolci G, Milic J, et al. The dynamic association between frailty, CD4 and CD4/CD8 ratio in people aging with HIV. PLoS One. 2019;14(2):e0212283. https://doi.org/10.1371/journal.pone.0212283.CrossRefPubMedPubMedCentral

61.

Branas F, Jimenez Z, Sanchez-Conde M, Dronda F, Lopez-Bernaldo De Quiros JC, Perez-Elias MJ, et al. Frailty and physical function in older HIV-infected adults. Age Ageing. 2017;46(3):522–6. https://doi.org/10.1093/ageing/afx013.CrossRefPubMed

62.

Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119:51–83. https://doi.org/10.1016/B978-0-12-407707-2.00002-3.CrossRefPubMedPubMedCentral

63.

Hunt PW, Lee SA, Siedner MJ. Immunologic biomarkers, morbidity, and mortality in treated HIV infection. J Infect Dis. 2016;214(Suppl 2):S44–50. https://doi.org/10.1093/infdis/jiw275.CrossRefPubMedPubMedCentral

64.

Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE, et al. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013;208(2):249–59. https://doi.org/10.1093/infdis/jit147.CrossRefPubMedPubMedCentral

65.

Margolick JB, Bream JH, Martinez-Maza O, Lopez J, Li X, Phair JP, et al. Frailty and circulating markers of inflammation in HIV+ and HIV- men in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2017;74(4):407–17. https://doi.org/10.1097/QAI.0000000000001261.CrossRefPubMedPubMedCentral

66.

Erlandson KM, Ng DK, Jacobson LP, Margolick JB, Dobs AS, Palella FJ Jr, et al. Inflammation, immune activation, immunosenescence, and hormonal biomarkers in the frailty-related phenotype of men with or at risk for HIV infection. J Infect Dis. 2017;215(2):228–37. https://doi.org/10.1093/infdis/jiw523.CrossRefPubMed

67.

Zhang W, Nilles TL, Johnson JR, Margolick JB. Regulatory T cells, frailty, and immune activation in men who have sex with men in the multicenter AIDS cohort study. J Gerontol A Biol Sci Med Sci. 2015;70(12):1533–41. https://doi.org/10.1093/gerona/glv132.CrossRefPubMedPubMedCentral

68.

Margolick JB, Bream JH, Nilles TL, Li H, Langan SJ, Deng S, et al. Relationship between T-cell responses to CMV, markers of inflammation, and frailty in HIV-uninfected and HIV-infected men in the multicenter AIDS cohort study. J Infect Dis. 2018;218(2):249–58. https://doi.org/10.1093/infdis/jiy005.CrossRefPubMedPubMedCentral

69.

McAdams-DeMarco MA, Law A, Salter ML, Boyarsky B, Gimenez L, Jaar BG, et al. Frailty as a novel predictor of mortality and hospitalization in individuals of all ages undergoing hemodialysis. J Am Geriatr Soc. 2013;61(6):896–901. https://doi.org/10.1111/jgs.12266.CrossRefPubMedPubMedCentral

70.

Rockwood MR, MacDonald E, Sutton E, Rockwood K, Baron M. Canadian scleroderma research G. frailty index to measure health status in people with systemic sclerosis. J Rheumatol. 2014;41(4):698–705. https://doi.org/10.3899/jrheum.130182.CrossRefPubMed

71.

• Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK biobank participants. Lancet Public Health. 2018;3(7):e323–e32. https://doi.org/10.1016/S2468-2667(18)30091-4. This paper provides evidence that frailty is not limited to the geriatric population.CrossRefPubMedPubMedCentral

72.

Kooij KW, Wit FW, Schouten J, van der Valk M, Godfried MH, Stolte IG, et al. HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS. 2016;30(2):241–50. https://doi.org/10.1097/QAD.0000000000000910.CrossRefPubMed

73.

Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci. 2007;62(11):1279–86. https://doi.org/10.1093/gerona/62.11.1279.CrossRefPubMed

74.

Desquilbet L, Margolick JB, Fried LP, Phair JP, Jamieson BD, Holloway M, et al. Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic Syndr. 2009;50(3):299–306. https://doi.org/10.1097/QAI.0b013e3181945eb0.CrossRefPubMedPubMedCentral

75.

Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, et al. A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men. J Gerontol A Biol Sci Med Sci. 2011;66(9):1030–8. https://doi.org/10.1093/gerona/glr097.CrossRefPubMed

76.

Althoff KN, Jacobson LP, Cranston RD, Detels R, Phair JP, Li X, et al. Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men. J Gerontol A Biol Sci Med Sci. 2014;69(2):189–98. https://doi.org/10.1093/gerona/glt148.CrossRefPubMed

77.

Piggott DA, Muzaale AD, Mehta SH, Brown TT, Patel KV, Leng SX, et al. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS One. 2013;8(1):e54910. https://doi.org/10.1371/journal.pone.0054910.CrossRefPubMedPubMedCentral

78.

Piggott DA, Muzaale AD, Varadhan R, Mehta SH, Westergaard RP, Brown TT, et al. Frailty and cause-specific hospitalization among persons aging with HIV infection and injection drug use. J Gerontol A Biol Sci Med Sci. 2017;72(3):389–94. https://doi.org/10.1093/gerona/glw142.CrossRefPubMed

79.

Johs NA, Wu K, Tassiopoulos K, Koletar SL, Kalayjian RC, Ellis RJ, et al. Disability among middle-aged and older persons with human immunodeficiency virus infection. Clin Infect Dis. 2017;65(1):83–91. https://doi.org/10.1093/cid/cix253.CrossRefPubMedPubMedCentral

80.

Kelly SG, Wu K, Tassiopoulos K, Erlandson KM, Koletar SL, Palella FJ. Frailty is an independent risk factor for mortality, cardiovascular disease, bone disease, and diabetes among aging adults with human immunodeficiency virus. Clin Infect Dis. 2019;69(8):1370–6. https://doi.org/10.1093/cid/ciy1101.CrossRefPubMed

81.

Erlandson KM, Wu K, Koletar SL, Kalayjian RC, Ellis RJ, Taiwo B, et al. Association between frailty and components of the frailty phenotype with modifiable risk factors and antiretroviral therapy. J Infect Dis. 2017;215(6):933–7. https://doi.org/10.1093/infdis/jix063.CrossRefPubMedPubMedCentral

82.

Zeballos D, Lins L, Brites C. Frailty and its association with health related quality of life in older HIV patients, in Salvador. Brazil AIDS Res Hum Retroviruses. 2019;35(11–12):1074–81. https://doi.org/10.1089/AID.2019.0103.CrossRefPubMed

83.

Pathai S, Gilbert C, Weiss HA, Cook C, Wood R, Bekker LG, et al. Frailty in HIV-infected adults in South Africa. J Acquir Immune Defic Syndr. 2013;62(1):43–51. https://doi.org/10.1097/QAI.0b013e318273b631.CrossRefPubMedPubMedCentral

84.

Bandeen-Roche K, Seplaki CL, Huang J, Buta B, Kalyani RR, Varadhan R, et al. Frailty in older adults: a nationally representative profile in the United States. J Gerontol A Biol Sci Med Sci. 2015;70(11):1427–34. https://doi.org/10.1093/gerona/glv133.CrossRefPubMedPubMedCentral

85.

Gustafson DR, Shi Q, Thurn M, Holman S, Minkoff H, Cohen M, et al. Frailty and Constellations of Factors in Aging HIV-infected and Uninfected Women--The Women's Interagency HIV Study. J Frailty Aging. 2016;5(1):43–8. https://doi.org/10.14283/jfa.2016.79.CrossRefPubMedPubMedCentral

86.

Womack JA, Goulet JL, Gibert C, Brandt CA, Skanderson M, Gulanski B, et al. Physiologic frailty and fragility fracture in HIV-infected male veterans. Clin Infect Dis. 2013;56(10):1498–504. https://doi.org/10.1093/cid/cit056.CrossRefPubMedPubMedCentral

87.

Bregigeon S, Galinier A, Zaegel-Faucher O, Cano CE, Obry V, Laroche H, et al. Frailty in HIV infected people: a new risk factor for bone mineral density loss. AIDS. 2017;31(11):1573–7. https://doi.org/10.1097/QAD.0000000000001507.CrossRefPubMed

88.

Justice AC, McGinnis KA, Skanderson M, Chang CC, Gibert CL, Goetz MB, et al. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med. 2010;11(2):143–51. https://doi.org/10.1111/j.1468-1293.2009.00757.x.CrossRefPubMed

89.

Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis. 2012;54(7):984–94. https://doi.org/10.1093/cid/cir989.CrossRefPubMedPubMedCentral

90.

Akgun KM, Tate JP, Crothers K, Crystal S, Leaf DA, Womack J, et al. An adapted frailty-related phenotype and the VACS index as predictors of hospitalization and mortality in HIV-infected and uninfected individuals. J Acquir Immune Defic Syndr. 2014;67(4):397–404. https://doi.org/10.1097/QAI.0000000000000341.CrossRefPubMedPubMedCentral

91.

Escota GV, Patel P, Brooks JT, Bush T, Conley L, Baker J, et al. Short communication: the veterans aging cohort study index is an effective tool to assess baseline frailty status in a contemporary cohort of HIV-infected persons. AIDS Res Hum Retrovir. 2015;31(3):313–7. https://doi.org/10.1089/AID.2014.0225.CrossRefPubMed

92.

Guaraldi G, Brothers TD, Zona S, Stentarelli C, Carli F, Malagoli A, et al. A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. AIDS. 2015;29(13):1633–41. https://doi.org/10.1097/QAD.0000000000000753.CrossRefPubMed

93.

Brothers TD, Kirkland S, Theou O, Zona S, Malagoli A, Wallace LMK, et al. Predictors of transitions in frailty severity and mortality among people aging with HIV. PLoS One. 2017;12(10):e0185352. https://doi.org/10.1371/journal.pone.0185352.CrossRefPubMedPubMedCentral

94.

Ho Tsong Fang R, Colantonio AD, Uittenbogaart CH. The role of the thymus in HIV infection: a 10 year perspective. AIDS. 2008;22(2):171–84. https://doi.org/10.1097/QAD.0b013e3282f2589b.CrossRefPubMed

95.

Guaraldi G, Franconi I, Milic J, Besutti G, Pintassilgo I, Scaglioni R, et al. Thymus Imaging Detection and Size Is Inversely Associated With Metabolic Syndrome and Frailty in People With HIV. Open Forum Infect Dis. 2019;6(10):ofz435. https://doi.org/10.1093/ofid/ofz435.CrossRefPubMedPubMedCentral

96.

Yeoh HL, Cheng AC, Cherry CL, Weir JM, Meikle PJ, Hoy JF, et al. Immunometabolic and lipidomic markers associated with the frailty index and quality of life in aging HIV+ men on antiretroviral therapy. EBioMedicine. 2017;22:112–21. https://doi.org/10.1016/j.ebiom.2017.07.015.CrossRefPubMedPubMedCentral

97.

Hawkins KL, Zhang L, Ng DK, Althoff KN, Palella FJ Jr, Kingsley LA, et al. Abdominal obesity, sarcopenia, and osteoporosis are associated with frailty in men living with and without HIV. AIDS. 2018;32(10):1257–66. https://doi.org/10.1097/QAD.0000000000001829.CrossRefPubMed

98.

Ding Y, Lin H, Liu X, Wong FY, Sun YV, Marconi VC, et al. Higher prevalence of frailty among a sample of HIV-infected middle-aged and older Chinese adults is associated with neurocognitive impairment and depressive symptoms. J Infect Dis. 2017;215(5):687–92. https://doi.org/10.1093/infdis/jix032.CrossRefPubMed

99.

Marquine MJ, Umlauf A, Rooney AS, Fazeli PL, Gouaux BD, Paul Woods S, et al. The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr. 2014;65(2):190–7. https://doi.org/10.1097/QAI.0000000000000008.CrossRefPubMedPubMedCentral

100.

Onen NF, Patel P, Baker J, Conley L, Brooks JT, Bush T, et al. Frailty and Pre-Frailty in a Contemporary Cohort of HIV-Infected Adults. J Frailty Aging. 2014;3(3):158–65. https://doi.org/10.14283/jfa.2014.18.CrossRefPubMedPubMedCentral

101.

Underwood J, Winston A. Guidelines for evaluation and management of cognitive disorders in HIV-positive individuals. Curr HIV/AIDS Rep. 2016;13(5):235–40. https://doi.org/10.1007/s11904-016-0324-x.CrossRefPubMedPubMedCentral

102.

Wallace LM, Ferrara M, Brothers TD, Garlassi S, Kirkland SA, Theou O, et al. Lower frailty is associated with successful cognitive aging among older adults with HIV. AIDS Res Hum Retrovir. 2017;33(2):157–63. https://doi.org/10.1089/AID.2016.0189.CrossRefPubMedPubMedCentral

103.

Erlandson KM, Perez J, Abdo M, Robertson K, Ellis RJ, Koletar SL, et al. Frailty, neurocognitive impairment, or both in predicting poor health outcomes among adults living with human immunodeficiency virus. Clin Infect Dis. 2019;68(1):131–8. https://doi.org/10.1093/cid/ciy430.CrossRefPubMed

104.

Zamudio-Rodriguez A, Belaunzaran-Zamudio PF, Sierra-Madero JG, Cuellar-Rodriguez J, Crabtree-Ramirez BE, Alcala-Zermeno JL, et al. Association between frailty and HIV-associated neurodegenerative disorders among older adults living with HIV. AIDS Res Hum Retrovir. 2018;34(5):449–55. https://doi.org/10.1089/AID.2017.0100.CrossRefPubMedPubMedCentral

105.

Theou O, Brothers TD, Pena FG, Mitnitski A, Rockwood K. Identifying common characteristics of frailty across seven scales. J Am Geriatr Soc. 2014;62(5):901–6. https://doi.org/10.1111/jgs.12773.CrossRefPubMed

106.

Guaraldi G, Malagoli A, Theou O, Brothers TD, Wallace L, Torelli R, et al. Correlates of frailty phenotype and frailty index and their associations with clinical outcomes. HIV Med. 2017;18(10):764–71. https://doi.org/10.1111/hiv.12527.CrossRefPubMed

107.

Lee DJK, Mak MHW, Tan KY. Frailty in surgical preoperative evaluation and postoperative recovery. Curr Geriatr Rep. 2019;8:87–96. https://doi.org/10.1007/s13670-019-0278-0.CrossRef

108.

Singh HK, Del Carmen T, Freeman R, Glesby MJ, Siegler EL. From one syndrome to many: incorporating geriatric consultation into HIV care. Clin Infect Dis. 2017;65(3):501–6. https://doi.org/10.1093/cid/cix311.CrossRefPubMed

109.

• Greene M, Steinman MA, McNicholl IR, Valcour V. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc. 2014;62(3):447–53. https://doi.org/10.1111/jgs.12695. This important paper reviews the underappreciated risks of polypharmacy in PLWH.CrossRefPubMedPubMedCentral

110.

Greene M, Justice AC, Covinsky KE. Assessment of geriatric syndromes and physical function in people living with HIV. Virulence. 2017;8(5):586–98. https://doi.org/10.1080/21505594.2016.1245269.CrossRefPubMed

111.

Erlandson KM, Schrack JA, Jankowski CM, Brown TT, Campbell TB. Functional impairment, disability, and frailty in adults aging with HIV-infection. Curr HIV/AIDS Rep. 2014;11(3):279–90. https://doi.org/10.1007/s11904-014-0215-y.CrossRefPubMedPubMedCentral

112.

Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14(6):392–7. https://doi.org/10.1016/j.jamda.2013.03.022.CrossRefPubMedPubMedCentral

113.

Branas F, Ryan P, Troya J, Sanchez-Conde M. Geriatric-HIV Medicine: the geriatrician’s role. Eur Geriatr Med. 2019;10(2):259–65 doi-prg-443.webvpn.fjmu.edu.cn/10.1007/s41999-018-0144-1.CrossRefPubMed

114.

• Pilotto A, Cella A, Pilotto A, Daragjati J, Veronese N, Musacchio C, et al. Three Decades of comprehensive geriatric assessment: evidence coming from different healthcare settings and specific clinical conditions. J Am Med Dir Assoc. 2017;18(2):192 e1–e11. https://doi.org/10.1016/j.jamda.2016.11.004. This paper summarizes the evidence supporting the fundamental assessment and intervention tool employed by geriatricians.CrossRef

115.

Garrard JW, Cox NJ, Dodds RM, Roberts HC, Sayer AA. Comprehensive geriatric assessment in primary care: a systematic review. Aging Clin Exp Res. 2019;32:197–205. https://doi.org/10.1007/s40520-019-01183-w.CrossRefPubMedPubMedCentral

116.

Tinetti M, Huang A, Molnar F. The geriatrics 5M's: a new way of communicating what we do. J Am Geriatr Soc. 2017;65(9):2115. https://doi.org/10.1111/jgs.14979.CrossRefPubMed

117.

• Erlandson KM, Karris MY. HIV and aging: reconsidering the approach to management of comorbidities. Infect Dis Clin North Am. 2019;33(3):769–86. https://doi.org/10.1016/j.idc.2019.04.005. This is an up-to-date review of the clinical issues in aging PLWH.CrossRefPubMedPubMedCentral

118.

Siegler EL, Burchett CO, Glesby MJ. Older people with HIV are an essential part of the continuum of HIV care. J Int AIDS Soc. 2018;21(10):e25188. https://doi.org/10.1002/jia2.25188.CrossRefPubMedPubMedCentral

119.

Bitas C, Jones S, Singh HK, Ramirez M, Siegler E, Glesby M. Adherence to recommendations from comprehensive geriatric assessment of older individuals with HIV. J Int Assoc Provid AIDS Care. 2019;18:2325958218821656. https://doi.org/10.1177/2325958218821656.CrossRefPubMedPubMedCentral

120.

Walston J, Buta B, Xue QL. Frailty screening and interventions: considerations for clinical practice. Clin Geriatr Med. 2018;34(1):25–38. https://doi.org/10.1016/j.cger.2017.09.004.CrossRefPubMedPubMedCentral

121.

Erlandson KM, MaWhinney S, Wilson M, Gross L, McCandless SA, Campbell TB, et al. Physical function improvements with moderate or high-intensity exercise among older adults with or without HIV infection. AIDS. 2018;32(16):2317–26. https://doi.org/10.1097/QAD.0000000000001984.CrossRefPubMed

122.

O'Brien KK, Ibanez-Carrasco F, Solomon P, Harding R, Cattaneo J, Chegwidden W, et al. Advancing research and practice in HIV and rehabilitation: a framework of research priorities in HIV, disability and rehabilitation. BMC Infect Dis. 2014;14:724. https://doi.org/10.1186/s12879-014-0724-8.CrossRefPubMedPubMedCentral

123.

Debroy P, Lake JE, Sim M, Erlandson KM, Falutz J, Prado CM, et al. Lean mass declines consistently over 10 years in people living with HIV on antiretroviral therapy, with patterns differing by sex. Antivir Ther. 2019;24(5):383–7. https://doi.org/10.3851/IMP3312.CrossRefPubMedPubMedCentral

124.

Landers-Ramos RQ, Dondero KR. Exercise and protein supplementation for prevention and treatment of sarcopenia. Curr Geriatr Rep. 2019;8:202–9. https://doi.org/10.1007/s13670-019-00293-7.CrossRef

125.

Guaraldi G, Francesco D, Malagoli A, Zona S, Franconi I, Santoro A, et al. Compression of frailty in adults living with HIV. BMC Geriatr. 2019;19(1):229. https://doi.org/10.1186/s12877-019-1247-3.CrossRefPubMedPubMedCentral

126.

Molina JM, Grund B, Gordin F, Williams I, Schechter M, Losso M, et al. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. Lancet HIV. 2018;5(4):e172–e80. https://doi.org/10.1016/S2352-3018(18)30003-1.CrossRefPubMed

127.

Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, Del Amo VJ, et al. Beyond viral suppression of HIV - the new quality of life frontier. BMC Med. 2016;14(1):94. https://doi.org/10.1186/s12916-016-0640-4.CrossRefPubMedPubMedCentral

128.

• Woo J. Frailty, successful aging, resilience, and intrinsic capacity: a cross-disciplinary discourse of the aging process. Curr Geriatr Rep. 2019;8:67–71. https://doi.org/10.1007/s13670-019-0276-2. This paper introduces current models to consider factors related to successful aging of the growing population of the elderly world-wide.CrossRef

129.

Guaraldi G, Milic J. The interplay between frailty and intrinsic capacity in aging and HIV infection. AIDS Res Hum Retrovir. 2019;35(11–12):1013–22. https://doi.org/10.1089/AID.2019.0157.CrossRefPubMed

Title: Frailty in People Living with HIV
Author: Julian Falutz
Publication date: 01-06-2020
Publisher: Springer US
Keyword: Human Immunodeficiency Virus
Published in: Current HIV/AIDS Reports / Issue 3/2020
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-020-00494-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2020

The CAN-DO-IT Model: a Process for Developing and Refining Online Recruitment in HIV/AIDS and Sexual Health Research

Senotherapeutics and HIV-1 Persistence

Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure

Improving Care Outcomes for PLWH Experiencing Homelessness and Unstable Housing: a Synthetic Review of Clinic-Based Strategies

Artificial Intelligence and Machine Learning for HIV Prevention: Emerging Approaches to Ending the Epidemic

Ethical Considerations in HIV eHealth Intervention Research: Implications for Informational Risk in Recruitment, Data Maintenance, and Consent Procedures

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage